English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The role of soluble  soluble urokinase -type  plasminogen activator receptor  (suPAR) as a biological marker for TB treatment efficacy on active pulmonary TB-AFB(+) patients was investigated. Twenty pulmonary TB-AFB(+) patients participated in a cohort study for six months. The plasma suPAR level was measured using ELISA method before treatment, two months, four months and six months after treatment. At the same time clinical parameters were also measured. Results indicated that all patients ( n  = 20) showed highest plasma suPAR levels before treatment (median 12.775 ng/mL) and significantly decreased (  P  = .0001<.05,  R   2  = .890) after 2 months (median 8.019 ng/mL) and 4 months (median 5.771 ng/mL) of treatment, respectively. However, only slightly declined after 6 months therapy (median 5.009 ng/mL), near control group level (median 4.772 ng/mL). Interestingly, the significant reduced of suPAR level was parallel to treatment efficacy and correlated with other clinical and laboratory parameters, that is, decreasing of patients' complaints, increasing of BMI ( r  = −0.281), thoracic imaging improvement, sputum conversion, decreasing of ESR ( r  = 0.577) and monocytes count ( r  = 0.536) with exception the width of lesion in thoracic imaging.  In conclusion, the suPAR level in could reflect the progress of TB therapy.

The Soluble PlasminogenActivator Receptoras a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients